Akebia Therapeutics Inks $22M
Cincinnati-based Akebia Therapeutics has closed on $22 million in Series B financing. Existing shareholders Novartis Venture Fund and Venture Investors co-led the round, which also saw participation from Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital and new investors including AgeChem Venture Fund. Akebia develops pharmaceuticals focused on anemia and vascular disorders. The $22 million Series B round includes a $14 million first closing. In addition, the company has the right to access another $8 million through the end of 2011.
26 April 2011•2 mins read
